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Epilepsy is a disorder characterized by recurrent spontaneous electrical discharges within the brain which are manifested by clinical seizures. Four million patients in the USA are afflicted with this ailment; 20% of these have seizures which cannot be controlled sufficiently with existing medications to permit normal activities of everyday life. Epileptic seizures can be classified as primary epilepsies (35%) and partial epilepsies (65%).
Primary epilepsies (generalized convulsions) can be controlled with valproate (Depakote), carbamazepine (Tegretol), phenytoin (Dilantin), or phenobarbitol. Most of the partial epilepsies have resisted control with chemotherapeutic agents.
Current targets for therapeutic intervention with respect to epilepsy are (i) blocking of receptors of excitatory amino acids, (ii) modulating membrane ion channels (sodium and calcium) involved in neuronal membrane excitability and (iii) enhancing the neurotransmittory effect of gamma-aminobutyric acid (GABA)
(1) (I) is the principal inhibitory neurotransmitter in the mammalian central nervous system (CNS).3 It may inhibit mammalian CNS activity in numerous ways4 Inhibition of GABA uptake into neuronal and glial cell bodies5t6 by designing appropriate substrates. This has proved to be the most promising strategy. This methodology had some drawbacks: i) The secondary carbinol formed is unstable to storage and is readily converted to the corresponding ether dimer. ii) Dithienyl ketone is obtained in very low yields along with numerous side products and requires a tedious workup procedure. An improved synthesis of desmethyltiagabine, designed by us, is shown in scheme 11.
We now report practical syntheses of regioisomers of tiagabine (IV) that were amenable to scale up.
Scheme 111 depicts the first of our methods.
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